Sectors & IndustriesHealthcareMedical Devices

Best Medical Device Stocks to Buy Now (2026)

Top medical device stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best medical device stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best medical equipment stocks to buy right now are:

Bioventus (NASDAQ:BVS) is the #1 top medical device stock out of 138 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Bioventus (NASDAQ:BVS) is: Value: A, Growth: A, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: C.

Bioventus (NASDAQ:BVS) has a Due Diligence Score of 41, which is 11 points higher than the medical device industry average of 30.

BVS passed 13 out of 33 due diligence checks and has strong fundamentals. Bioventus has seen its stock return 61.61% over the past year, overperforming other medical device stocks by 124 percentage points.

Bioventus has an average 1 year price target of $15.00, an upside of 40.85% from Bioventus's current stock price of $10.65.

Bioventus stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Bioventus, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Electromed (NYSEMKT:ELMD) is the #2 top medical device stock out of 138 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Electromed (NYSEMKT:ELMD) is: Value: C, Growth: C, Momentum: C, Sentiment: A, Safety: A, Financials: A, and AI: B.

Electromed (NYSEMKT:ELMD) has a Due Diligence Score of 45, which is 15 points higher than the medical device industry average of 30.

ELMD passed 15 out of 33 due diligence checks and has strong fundamentals. Electromed has seen its stock return 22.15% over the past year, overperforming other medical device stocks by 85 percentage points.

Electromed has an average 1 year price target of $36.00, an upside of 34.03% from Electromed's current stock price of $26.86.

Electromed stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Electromed, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Viemed Healthcare (NASDAQ:VMD) is the #3 top medical device stock out of 138 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Viemed Healthcare (NASDAQ:VMD) is: Value: C, Growth: B, Momentum: B, Sentiment: C, Safety: C, Financials: B, and AI: B.

Viemed Healthcare (NASDAQ:VMD) has a Due Diligence Score of 49, which is 19 points higher than the medical device industry average of 30.

VMD passed 16 out of 33 due diligence checks and has strong fundamentals. Viemed Healthcare has seen its stock return 26.69% over the past year, overperforming other medical device stocks by 89 percentage points.

Out of 8 medical device stocks that have issued dividends in the past year, the 3 medical device stocks with the highest dividend yields are:

Abbott Laboratories (NYSE:ABT) has an annual dividend yield of 2.8%, which is 1 percentage points higher than the medical device industry average of 1.34%. Abbott Laboratories's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Abbott Laboratories's dividend has shown consistent growth over the last 10 years.

Abbott Laboratories's dividend payout ratio of 68% indicates that its dividend yield is sustainable for the long-term.

Smith & Nephew (NYSE:SNN) has an annual dividend yield of 2.56%, which is 1 percentage points higher than the medical device industry average of 1.34%. Smith & Nephew's dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Smith & Nephew's dividend has shown consistent growth over the last 10 years.

Smith & Nephew's dividend payout ratio of 52.8% indicates that its dividend yield is sustainable for the long-term.

Iradimed (NASDAQ:IRMD) has an annual dividend yield of 1.39%, which is the same as the medical device industry average of 1.34%. Iradimed's dividend payout is not stable, having dropped more than 10% three times in the last 10 years. Iradimed's dividend has not shown consistent growth over the last 10 years.

Iradimed's dividend payout ratio of 65.1% indicates that its dividend yield is sustainable for the long-term.

Medical device stocks were up 0.58% in the last day, and down -1.58% over the last week. Sight Sciences was the among the top gainers in the medical devices industry, gaining 23.02% yesterday.

Sight Sciences shares are trading higher. The company reported Q1 financial results and raised its FY26 sales guidance with its midpoint above estimates.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued medical device stocks right now are:

Inmode (NASDAQ:INMD) is the most undervalued medical device stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Inmode has a valuation score of 71, which is 57 points higher than the medical device industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Inmode's stock has dropped -2.11% in the past year. It has overperformed other stocks in the medical device industry by 60 percentage points.

Conmed (NYSE:CNMD) is the second most undervalued medical device stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Conmed has a valuation score of 71, which is 57 points higher than the medical device industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Conmed's stock has dropped -31.98% in the past year. It has overperformed other stocks in the medical device industry by 30 percentage points.

Bioventus (NASDAQ:BVS) is the third most undervalued medical device stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Bioventus has a valuation score of 43, which is 29 points higher than the medical device industry average of 14. It passed 3 out of 7 valuation due diligence checks.

Bioventus's stock has gained 61.61% in the past year. It has overperformed other stocks in the medical device industry by 124 percentage points.

61.46% of medical device stocks rated by analysts are a strong buy right now. On average, analysts expect medical device stocks to rise by 36.22% over the next year.

7.45% of medical device stocks have a Zen Rating of A (Strong Buy), 20.21% of medical device stocks are rated B (Buy), 50% are rated C (Hold), 17.02% are rated D (Sell), and 5.32% are rated F (Strong Sell).